Intranasal drug delivery of didanosine-loaded chitosan nanoparticles for brain targeting; An attractive route against infections caused by aids viruses

Journal of Drug Targeting

Volumn 18, Issue 5, 2010, Pages 381-388

  Al Ghananeem, Abeer M ^a   Saeed, Hayder ^a   Florence, Rebecca ^a   Yokel, Robert A ^a   Malkawi, Ahmad H ^a  

^a University of Kentucky   (United States)

Author keywords

Brain targeting; Didanosine; Intranasal; Nanoparticles; Pharmacokinetics

Indexed keywords

CHITOSAN; DIDANOSINE; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG TARGETING; GELATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ADMINISTRATION, INTRANASAL; ANIMALS; BRAIN; CHITOSAN; CHROMATOGRAPHY, LIQUID; DIDANOSINE; DISEASE MODELS, ANIMAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HIV INFECTIONS; MALE; MASS SPECTROMETRY; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 77952133496     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/10611860903483396     Document Type: Article

References (25)

1. Albert A. (1953). Quantitative studies of the avidity of naturally occurring substances for trace metals. Biochem J, 54: 646-654.
2. Al-Ghananeem AM, Traboulsi AA, Dittert LW, Hussain AA. (2002). Targeted brain delivery of 17 beta-estradiol via nasally administered water soluble prodrugs. AAPS PharmSciTech, 3: E5.
3. Anderson BD, Galinsky RE, Baker DC, Chi SC, Hoesterey BL, Morgan ME, Murakami K, Mitsuya H. (1992). Approaches toward the optimization of CNS uptake of anti-AIDS agents. J Control Release, 19: 219-230.
4. Anderson BD, Morgan ME, Singhal D. (1995). Enhanced oral bioavailability of DDI after administration of 6-Cl-ddP, an adenosine deaminase-activated prodrug, to chronically catheterized rats. Pharm Res, 12: 1126-1133.
5. Anderson BD, Wygant MB, Xiang TX, Waugh WA, Stella V. (1988). Preformulation solubility and kinetic studies of 2β,3βdideoxypurine nucleosides: potential anti-AIDS agents. Int J Pharm, 45: 27-37.
6. Artursson P, Lindmark T, Davis SS, Illum L. (1994). Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm Res, 11: 1358-1361.
7. Begley DJ. (1996). The blood-brain barrier: principles for targeting peptides and drugs to the central nervous system. J Pharm Pharmacol, 48: 136-146.
8. Bramer SL, Au JL, Wientjes MG. (1993). Gastrointestinal and hepatic first-pass elimination of 2β,3β-dideoxyinosine in rats. J Pharmacol Exp Ther, 265: 731-738.
9. Butler KM, Husson RN, Balis FM, Brouwers P, Eddy J, el-Amin D, Gress J, Hawkins M, Jarosinski P, Moss H. (1991). Dideoxyinosine in children with symptomatic human immunodeficiency virus infection. N Engl J Med, 324: 137-144.
10. Fernandez-Urrusuno R, Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. (1999). Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharm Res, 16: 1576-1581.
11. Frey WH. (2002). Bypassing the blood-brain barrier to deliver therapeutic agents to the brain and spinal cord. Drug Delivery Technol, 2: 46-49.
12. Hartman NR, Yarchoan R, Pluda JM, Thomas RV, Marczyk KS, Broder S, Johns DG. (1990). Pharmacokinetics of 2β,3β-dideoxyadenosine and 2β,3β-dideoxyinosine in patients with severe human immunodeficiency virus infection. Clin Pharmacol Ther, 47: 647-654. (Pubitemid 20190104)
13. Hong M, Schlichter L, Bendayan R. (2001). A novel zidovudine uptake system in microglia. J Pharmacol Exp Ther, 296: 141-149.
14. Huang CH, Kimura R, Nassar RB, Hussain A. (1985). Mechanism of nasal absorption of drugs I: Physicochemical parameters influencing the rate of in situ nasal absorption of drugs in rats. J Pharm Sci, 74: 608-611.
15. Hussain AA. (1998). Intranasal drug delivery. Adv Drug Deliv Rev, 29: 39-49.
16. Illum L. (2003). Is nose-to-brain transport of drugs in man a reality. Journal of Pharmacy and Pharmacology J Pharm Pharmacol, 56: 3-17.
17. Janes KA, Calvo P, Alonso MJ. (2001). Polysaccharide colloidal particles as delivery systems for macromolecules. Adv Drug Deliv Rev, 47: 83-97.
18. Jogani VV, Shah PJ, Mishra P, Mishra AK, Misra AR. (2007). Nose-tobrain delivery of tacrine. J Pharm Pharmacol, 59: 1199-1205.
19. Kao HD, Traboulsi A, Itoh S, Dittert L, Hussain A. (2000). Enhancement of the systemic and CNS specific delivery of L-dopa by the nasal administration of its water soluble prodrugs. Pharm Res, 17: 978-984.
20. Kawaguchi T, Hasegawa T, Juni K, Seki T. (1991). Int J Pharmaceut, 77: 71.
21. Morgan ME, Chi SC, Murakami K, Mitsuya H, Anderson BD. (1992). Central nervous system targeting of 2β,3β-dideoxyinosine via adenosine deaminase-activated 6-halo-dideoxypurine prodrugs. Antimicrob Agents Chemother, 36: 2156-2165.
22. Rapoport SI. (1996). Modulation of blood-brain barrier permeability. J Drug Target, 3: 417-425.
23. Seki T, Kawaguchi T, Juni K. (1990). Enhanced delivery of zidovudine through rat and human skin via ester prodrugs. Pharm Res, 7: 948-952.
24. Sinko PJ, Patel NR, Hu P. (1994). Site-specific oral absorption of didanosine: in situ characterization and correlation with extent of absorption in vivo. Int J Pharm, 109: 125-133.
25. Wang YY, Lai SK, Suk JS, Pace A, Cone R, Hanes J. (2008). Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that "slip" through the human mucus barrier. Angew Chem Int Ed Engl, 47: 9726-9729.